Kestra Medical Technologies Announces Strategic Collaboration with Biobeat Technologies to Expand Diagnostic Insight for Wearable Defibrillator Patients During Cardiac Recovery
Rhea-AI Summary
Kestra Medical Technologies (Nasdaq: KMTS) announced a strategic collaboration and exclusive license/co-development with Biobeat to integrate Biobeat’s FDA-cleared, cuffless 24-hour ambulatory blood pressure monitoring (ABPM) into the ASSURE Wearable Cardioverter Defibrillator (WCD) ecosystem.
The agreement includes a $5 million equity investment in Biobeat’s Series B and aims to provide continuous, noninvasive blood pressure data to support at-home cardiac recovery. Kestra cited its ACE-PAS study where 72% of patients were hypertensive, underscoring the partnership’s clinical relevance for guideline-directed medical therapy optimization.
Positive
- $5 million equity investment in Biobeat Series B
- Exclusive license and co-development arrangement with Biobeat
- Biobeat’s FDA-cleared 24-hour cuffless ABPM device
- ACE-PAS: 72% of ASSURE patients were hypertensive
Negative
- None.
News Market Reaction
On the day this news was published, KMTS declined 5.85%, reflecting a notable negative market reaction. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $81M from the company's valuation, bringing the market cap to $1.31B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
KMTS fell 4.18% while peers were mixed: EMBC (+0.71%), PLSE (+0.21%), BLFS (‑3.8%), STAA (‑0.5%), ATRC (‑9.41%). No broad, one-direction sector move evident.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 30 | Conference appearance | Neutral | +2.0% | Announcement of J.P. Morgan Healthcare Conference presentation. |
| Dec 11 | Earnings results | Positive | +1.6% | Strong Q2 FY2026 growth and raised full-year revenue guidance. |
| Dec 03 | Earnings date | Neutral | +12.2% | Scheduling and call details for upcoming Q2 FY2026 results. |
| Dec 02 | Equity offering | Negative | -6.8% | Pricing of upsized primary public share offering at $23.00. |
| Dec 01 | Equity offering | Negative | -8.5% | Announcement of proposed primary public offering of common shares. |
Across the last five news events, price moves consistently aligned with the apparent news tone, including positive reactions to earnings and negative reactions to equity offerings.
Over the past few months, Kestra issued two equity offerings in early December 2025, which saw negative price reactions, followed by a strong rebound around the Q2 FY2026 earnings report on Dec 11, 2025 that featured 53% revenue growth and raised guidance. A later appearance announcement for the J.P. Morgan Healthcare Conference on Dec 30, 2025 also drew a modest gain. Against this backdrop, the new collaboration with Biobeat extends the company’s cardiac recovery ecosystem beyond prior financial and conference-focused updates.
Market Pulse Summary
The stock moved -5.8% in the session following this news. A negative reaction despite a strategically constructive collaboration would contrast with past behavior, where price moves generally aligned with news tone, including gains after strong Q2 FY2026 results and raised guidance. Investors may have focused on execution risk around integrating Biobeat’s technology or on the modest scale of the $5 million investment. Prior declines around equity offerings also show that capital structure concerns have influenced trading and could color responses to new initiatives.
Key Terms
wearable cardioverter defibrillator medical
ambulatory blood pressure monitoring medical
photoplethysmography-based medical
fda-cleared regulatory
guideline-directed medical therapy medical
AI-generated analysis. Not financial advice.
KIRKLAND, Wash., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced a strategic collaboration with Biobeat Technologies, Ltd. to expand diagnostic insight for patients prescribed the ASSURE® Wearable Cardioverter Defibrillator (WCD). The agreement is anchored by an exclusive license and co-development arrangement and includes a
Biobeat has developed the only clinically validated, FDA-cleared cuffless, patch-worn ambulatory blood pressure monitoring (ABPM) device, leveraging photoplethysmography-based sensing to deliver continuous, noninvasive blood pressure measurement over a 24-hour period for hypertension diagnosis and management in the outpatient cardiac recovery setting. Kestra intends to integrate Biobeat’s technology into its product portfolio to make ABPM data available for patients prescribed the ASSURE WCD.
Kestra recently published the largest prospective real-world study of wearable defibrillators to date and insights from ASSURE Wearable Cardioverter Defibrillator Clinical Evaluation Post-Approval Study (ACE-PAS) underscore the clinical relevance of the collaboration with Biobeat. Seventy-two percent (
“Health care providers have consistently told us that better visibility to blood pressures during cardiac recovery would meaningfully support clinical decision making,” said Brian Webster, President and CEO of Kestra. “This collaboration allows us to expand the clinical insights available during recovery while reinforcing ASSURE as a flexible platform designed to support at-home patient care.”
Arik Ben Ishay, CEO of Biobeat, added, “Kestra has built a scalable platform focused on protecting and supporting patients during cardiac recovery. We are excited to collaborate with Kestra as they explore how our FDA-cleared, 24-hour blood pressure monitoring for hypertension diagnosis may complement their Cardiac Recovery System® platform and expand the clinical insights available to care teams managing complex cardiac patients.”
About Kestra
Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com.
About Biobeat
Biobeat is an innovative company with operations in Tel Aviv, Israel and Boca Raton, Florida. Biobeat is focused on revolutionizing the blood pressure monitoring landscape by expanding the use of ABPM for hypertensive patients and providing 24-hour blood pressure data that allows for patient comfort and uninterrupted sleep while capturing critical nighttime blood pressure measurements seamlessly and accurately. For more information visit https://www.bio-beat.com
Forward-Looking Statements
Except where otherwise noted, the information contained in this press release is as of January 13, 2026. Statements in this press release that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; and other risks and uncertainties, including those described under the heading “Risk Factors” in Kestra’s Annual Report on Form 10-K for the fiscal year ended April 30, 2025 filed with the U.S. Securities and Exchange Commission (“SEC”) on July 17, 2025, and in other periodic reports filed by Kestra with the SEC. These filings are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9f7a5dd8-eb80-4db2-b977-db8bba695bf8
Media contact Rhiannon Pickus rhiannon.pickus@kestramedical.com Investor contact Neil Bhalodkar neil.bhalodkar@kestramedical.com
FAQ
What did Kestra (KMTS) announce on January 13, 2026?
How will Biobeat’s FDA-cleared ABPM affect ASSURE WCD patients (KMTS)?
What clinical finding did Kestra cite to justify the KMTS–Biobeat collaboration?
How much equity did Kestra invest in Biobeat and in what financing round?
Is Biobeat’s blood pressure monitor cleared by regulators for outpatient use?
